Gilead Sciences (GILD) Stock: What to Know Before the Market Opens on December 22, 2025
Gilead Sciences shares traded near $124.29, up 2.35% premarket Monday, after the company signed a three-year U.S. drug-pricing agreement and reported late-stage HIV pipeline progress. The deal includes discounts on key medicines and a direct-to-patient program, with Gilead expecting a manageable financial impact. Shares remain close to their 52-week high of $128.70.